These findings suggest that the expression of IDO1/SLC2A1 may be an independent prognostic indicator for PC, and inhibiting of IDO1 and GLUT1 with inhibitors may offer potential benefits for PC patients. Here, IDO1 is linked to pachyonychia congenita.